News | 53Biologics

June 30, 2026 Patricia De La Madrid Comments: 0

Is Your Analytical Package Ready for GMP Biologics Manufacturing?

A biologic can be ready for GMP manufacturing in the process sense and still not be ready in the analytical sense becasue the analytical package is poor defined. This is one of the most common late-stage bottlenecks in Biologics Production. The upstream process has been developed. The downstream strategy is reasonably defined. The cell bank, plasmid DNA construct or production strain is available. The batch size is agreed. The manufacturing slot is being discussed. Everything seems to be moving....

53Biologics different paths CDMO change late in development

June 18, 2026 Patricia De La Madrid Comments: 0

Changing CDMO Late in Development: What Biologics Teams Should Know

Changing CDMO late in development may sometimes be necessary. Capacity may no longer fit the program. Timelines may have shifted. The original partner may not offer GMP manufacturing, integrated analytics, fill-finish or the flexibility needed for the next stage. In other cases, the issue is less obvious. Communication becomes slow, technical discussions lose depth, or every change seems to require another transfer, another vendor, another delay. On paper, moving to a new CDMO can look like a pr...

May 26, 2026 Patricia De La Madrid Comments: 0

Antibody manufacturing: Beyond Capacity and Price

Antibody manufacturing decisions are often reduced to two variables: capacity and price. While both are important, they rarely determine the true success of a program. Antibody Manufacturing Is a System, Not a Service One of the most overlooked aspects of antibody manufacturing is that it behaves as an interconnected system rather than a sequence of independent steps. Upstream performance, downstream purification, analytics, and GMP documentation are often treated as separate workstreams. In pra...

May 12, 2026 Patricia De La Madrid Comments: 0

How a CDMO Accelerates Drug Development

In today’s biologics landscape, drug development is no longer limited by scientific discovery alone. It is constrained by how efficiently that discovery is translated into scalable, compliant manufacturing. This is where a CDMO can either act as a bottleneck or as a true accelerator. Drug Development Acceleration Is About Reducing Iterations, Not Just Time A common misconception is that CDMOs accelerate drug development by doing things faster. In reality, the most effective CDMOs reduce the nu...

April 21, 2026 Patricia De La Madrid Comments: 0

Recombinant Protein Production Under GMP: Key Decisions That Define Success

When companies evaluate GMP recombinant protein manufacturing, discussions often revolve around timelines, batch size or price per gram. For companies already familiar with the industry and now entering the decision stage, the key question is not simply who can manufacture the protein, but who can manufacture it reliably, efficiently, and with a realistic path to scale. GMP Manufacturing Starts with the Wrong Question: “How Fast Can You Produce?” Many sponsors begin vendor selection by aski...

April 7, 2026 Patricia De La Madrid Comments: 0

Why GMP Readiness Starts During Drug Development, Not at Clinical Phase

Most biotech teams assume GMP readiness begins when a product enters clinical phases. In reality, the foundations of GMP are built much earlier, during drug development, often without being explicitly labeled as such. Drug Development Decisions That Quietly Define GMP Success During early drug development, teams focus on speed, proof of concept, and technical feasibility. However, several “invisible” decisions made at this stage have long-term GMP implications. For example: Selecting raw mat...

March 25, 2026 Patricia De La Madrid Comments: 0

How to Scale Manufacturing Without Losing Quality or Compliance

Scaling manufacturing is one of the most misunderstood transitions in biologics development. Many teams assume that if a process works at small scale, it will behave similarly at larger volumes. In reality, scale up in manufacturing is not a linear expansion, it is a transformation. At 53Biologics, we support companies navigating this transition daily, helping them scale manufacturing without compromising product quality or GMP expectations. Scale Up in Manufacturing Is a Biological Problem, Not...

March 25, 2026 Patricia De La Madrid Comments: 0

53Biologics boosts its GMP biomanufacturing expansion with an investment led by Ren Life Sciences and supported by Inveready

VALLADOLID, MARCH 25, 2026 53Biologics, a biotechnology company specialising in the development and manufacturing of biological drugs, has announced the closing of a strategic financing round led by the specialist European private equity firm Ren Life Sciences. Existing partners of the company co-invested, including leading Spanish innovation fund Inveready The primary objective of this transaction is to consolidate 53Biologics’ position as a key player in Europe’s biomanufacturing i...

Aseptic fill and finish grade A isolator in GMP cleanroom environment at 53Biologics

March 11, 2026 Patricia De La Madrid Comments: 0

Understanding the Manufacturing Responsibilities for Drug Substances and Drug Products

Understanding the responsibilities involved in Drug Substance and Drug Product manufacturing is essential for making the right strategic decisions. Many biotech companies approaching clinical phases discover that the distinction between these two stages affects regulatory compliance, timelines, and manufacturing partnerships. Working with an experienced CDMO is often the most efficient way to manage these responsibilities while maintaining compliance with international regulatory standards. Drug...

February 24, 2026 Patricia De La Madrid Comments: 0

GMP Manufacturing Pitfalls That Delay Biologics Production (and How to Avoid Them)

GMP manufacturing pitfalls that delay biologics production can increase costs, disrupt clinical timelines, and compromise regulatory readiness if not addressed early. In biologics development, delays rarely come from a single dramatic failure. More often, they result from small oversights during process development that later become major bottlenecks under GMP conditions. Whether you are working with microbial or mammalian systems, understanding common GMP manufacturing pitfalls is essential to...